420 Magazine Background

Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose

420 News

New Member
Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation


Author(s) Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Simon RM, Rosenberg SA.
Journal, Volume, Issue Annals of Internal Medicine 1979;91:819-824.
Major outcome(s) 14 of 15 patients had decreased vomiting and nausea
Indication Nausea/vomiting;Cancer;Cancer chemotherapy
Medication Delta-9-THC
Route(s) Inhalation;Oral
Dose(s) 10mg/m2 oral, 17mg smoking every 3 hours
Duration (days)
Participants 15 patients receiving high-dose methotrexate
Design Controlled study


Abstract

Fifteen patients with osteogenic sarcoma receiving high-dose methotrexate
chemotherapy were studied in a randomized, double-blind, placebo-controlled
trial of oral and smoked delta-9-tetrahydrocannabinol (THC) as an antiemetic.
Each patient served as his or her own control. Fourteen of 15 patients had a
reduction in nausea and vomiting on THC as compared to placebo.
Delta-9-tetrahydrocannabinol was significantly more effective than placebo in
reducing the number of vomiting and retching episodes, degree of nausea,
duration of nausea, and volume of emesis (P less than 0.001). There was a 72%
incidence of nausea and vomiting on placebo. When plasma THC concentrations
measured less than 5.0 ng/mL, 5.0 to 10.0 ng/mL, and greater than 10.0 ng/mL,
the incidences of nausea and vomiting were 44%, 21%, and 6%, respectively.
Delta-9-tetrahydrocannabinol appears to have significant antiemetic properties
when compared with placebo in patients receiving high-dose methotrexate.


Source: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation
 
Top Bottom